Solcitinib

产品说明书

Print
Chemical Structure| 1206163-45-2 同义名 : GLPG-0778; GSK-2586184; G154578; GSK2586184A
CAS号 : 1206163-45-2
货号 : A119338
分子式 : C22H23N5O2
纯度 : 99%+
分子量 : 389.45
MDL号 : MFCD26960569
存储条件:

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 : -
动物实验配方:
生物活性
描述 The Janus kinase and Signal Transducer and Activator of Transcription protein (JAK/STAT) pathway is known to be involved in inflammatory and neoplastic skin diseases, like psoriasis, atopic dermatitis, alopecia areata, vitiligo and melanoma. JAKs, a small family of kinases - JAK1, JAK2, JAK3 and Tyrosine Kinase 2 (TYK2), bind directly to the intracellular domains of Type I/II cytokine receptors and not to other classes of cytokine receptors. JAKs are located at the cytoplasmic tail of various cytokine receptors, and are activated upon receptor-ligand interaction. Due to the kinase activity, JAK activation results in auto-phosphorylation as well as phosphorylation of the cytokine receptor chains, and the combination of JAKs and the receptor form specific binding sites for one or more members of the STAT [signal transducer and activator of transcription] family. GSK2586184 (Solcitinib) is an orally active, competitive, potent, selective JAK1 inhibitor. In biochemical phosphorylation assays, GSK2586184 has an IC 50 of 9.8 nM, and shows 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively[2]. GSK2586184 was administered in two patients 400 mg twice daily for 48 days with moderate-to-severe ulcerative colitis (UC). The result showed that the JAK1 selective inhibitor GSK2586184 was well tolerated and induced clinical and endoscopic response in two patients with moderate-to-severe UC. GSK2586184, a Janus kinase 1 selective inhibitor, induced clinical and endoscopic response in ulcerative colitis, however, the study was discontinued at an early stage due to liver toxicity observed in systemic lupus patients receiving the drug[3].
作用机制 A ring nitrogen and the hydrogen associated with the adjacent exocyclic amine are involved in binding to the hinge region of the JAK1 kinase. This places the conserved cyclopropyl group in a lipophilic pocket.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.84mL

2.57mL

1.28mL

25.68mL

5.14mL

2.57mL

参考文献

[1]Adwan MH. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist. Curr Rheumatol Rep. 2017 Jan;19(1):3.

[2]Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR, Watson J, Wilson P, Simeoni M, Schifano LA, Reich K, Griffiths CE. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95. doi: 10.1111/bjd.14399. Epub 2016 Apr 7. PMID: 26785220.

[3]De Vries LCS, Ludbrook VJ, Hicks KJ, D'Haens GR. GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. BMJ Case Rep. 2017 Aug 7;2017:bcr2017221078. doi: 10.1136/bcr-2017-221078. PMID: 28790099; PMCID: PMC5624036.